RNAi Therapeutics Market Growth 2024-2025 | Alnylam's Vutrisiran, Arrowhead's Plozasiran, Roche's Strategic Deals, and Investment Trends in Hospitals & Healthcare

Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and Healthcare

RNA interference (RNAi) therapeutics have garnered significant attention due to their innovative approach in treating a range of diseases. As of 2025, this sector is evolving rapidly, with numerous advancements that have the potential to reshape the landscape of healthcare.

The following highlights showcase key developments from some of the leading companies in the Antisense RNAi therapeutics sector, including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and others.

Get the Free Sample Antisense RNAi Therapeutics Market research report now to gain exclusive insights into the latest advancements, market trends, and investment opportunities in the rapidly growing RNAi therapeutics sector: https://www.marketdigits.com/request/sample/4533

Advancements in RNAi Therapeutics

In 2024, significant strides were made in the RNAi therapeutics field, especially by key players like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals.

Alnylam Pharmaceuticals has made notable progress with Vutrisiran, a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). This RNAi therapeutic has shown a 28% reduction in mortality and cardiovascular events in Phase 3 trials. If approved, Vutrisiran could establish itself as a new standard of care for ATTR-CM. The company's expertise in RNAi technology continues to position it at the forefront of this innovative field.

Another significant player, Arrowhead Pharmaceuticals, advanced its RNAi-based Plozasiran into Phase 3 trials for treating cardiovascular conditions. This development signals the potential to address major unmet needs in heart disease through RNAi.

Strategic Collaborations and Partnerships

The RNAi therapeutics market is seeing increasing collaboration between major biopharma companies. Strategic partnerships are key drivers of innovation and market growth in this sector.

Roche and Ascidian Therapeutics entered into a partnership aimed at advancing RNA gene-editing technologies to target neurological diseases. This collaboration, worth up to $1.8 billion based on milestones, is expected to accelerate RNAi therapeutic development in genetic disorders.

Alnylam Pharmaceuticals also expanded its collaboration with Roche to develop and commercialize Zilebesiran, an investigational RNAi therapeutic for hypertension, currently in Phase 2 trials. This partnership represents an important step toward broadening the applications of RNAi therapeutics.

Mergers and Acquisitions Activity

In 2024, several major players in the RNAi therapeutics space have drawn attention as potential acquisition targets, reflecting the growing interest in this rapidly evolving market.

Arrowhead Pharmaceuticals, with its robust RNAi platform and promising late-stage cardiovascular treatments, has become a target for acquisition. The company's market capitalization of approximately $3.4 billion makes it a potential acquisition candidate for larger biopharma companies seeking to enter or expand their RNAi portfolios.

Additionally, Aurinia Pharmaceuticals, known for its Lupkynis treatment for lupus nephritis, has been a subject of acquisition speculation, with industry analysts estimating its value to be between $18 to $20 per share.

View the Complete 181 Pages Market Research Report on Antisense RNAi Therapeutics: https://www.marketdigits.com/antisense-rnai-therapeutics-market-1709541344

Regulatory Approvals and Market Expansion

2024 also witnessed significant regulatory progress, with several RNAi therapeutics advancing toward potential market approval.

Vutrisiran from Alnylam Pharmaceuticals has recently received regulatory approval for additional related indications, with expectations for broader FDA approval soon. This would cement its role in treating rare genetic diseases and cardiovascular conditions.

In addition, Plozasiran from Arrowhead Pharmaceuticals is progressing through Phase 3 trials and is poised for a potential regulatory approval for treating cardiovascular conditions, contributing to the rapid market expansion of RNAi therapies.

Competitive Landscape and Market Share

The competition in the RNAi therapeutics space is fierce, with several players positioning themselves as leaders in the field.

Alnylam Pharmaceuticals is particularly strong, with the approval and ongoing trials of Vutrisiran solidifying its market leadership in the RNAi therapeutics space for cardiovascular and rare diseases. The company's deep pipeline and advanced RNAi platform make it a formidable competitor in this high-growth sector.

Similarly, Arrowhead Pharmaceuticals is making its mark with its innovative RNAi platform, and its Plozasiran therapy shows significant promise for cardiovascular applications, adding to the company's increasing market share.

Another notable competitor, Avidity Biosciences, has demonstrated a 25% increase in dystrophin production in patients with Duchenne muscular dystrophy (DMD) after treatment with its RNAi-based therapy, further establishing its position in the competitive landscape of RNA-based therapies.

The RNAi therapeutics sector is rapidly evolving, with companies like Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Avidity Biosciences leading the charge in technological innovation and market expansion. Strategic collaborations, mergers, and acquisitions are set to play pivotal roles in shaping the future of RNAi therapies. With regulatory approvals advancing and promising results from clinical trials, RNAi therapeutics are poised to make significant impacts in treating cardiovascular, genetic, and rare diseases.

This sector is growing and the investors in the hospitals and healthcare industry must closely monitor these developments to understand the changing dynamics and potential investment opportunities in this promising field.

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.